Drug intelligence / Profile preview

ORB-TR

Development stage: Preclinical
Lead developer: Theradaptive
Modality: Recombinant Proteins and Enzymes
Administration: Implant

Overview

**ORB-TR** is an investigational, surgically implanted regenerative bone-graft product developed by Theradaptive for long-bone repair. It consists of Theradaptive's AMP2, an engineered material-binding variant of recombinant human bone morphogenetic protein 2, coated onto the synthetic, resorbable ReBOSSIS bone-void-filler scaffold. Local retention of AMP2 on the scaffold is intended to confine osteoinductive BMP2 activity to the implant site, supporting targeted bone regeneration while reducing off-target bone formation.

Other names: AMP2 on ReBOSSISAMP-2 on ReBOSSISAMP 2 on ReBOSSISAMP2-coated ReBOSSISAMP-2-coated ReBOSSISAMP 2-coated ReBOSSISReBOSSIS + AMP2

Targets

ACVR1 (Activin receptor type I)

Beyond the preview

Go deeper on ORB-TR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORB-TR.

Explore the full profile